miRecule Partners with GBI Biomanufacturing to Advance ARC Therapies

• miRecule, a biotechnology company focused on RNA therapies, has entered a strategic partnership with GBI Biomanufacturing, a contract development and manufacturing organisation (CDMO), to support the clinical supply of its Antibody-RNA Conjugate (ARC) products.

• The collaboration will combine GBI’s expertise in conjugation technologies and antibody manufacturing to advance the development of ARC therapies for rare diseases with unmet medical needs.

miRecule, a biotechnology company developing RNA-based therapies, has announced a new strategic partnership with GBI Biomanufacturing, a contract development and manufacturing organisation (CDMO), to accelerate the development and clinical supply of its innovative Antibody-RNA Conjugate (ARC) therapies. The collaboration aims to address the genetic causes of serious diseases, leveraging both antibody targeting and oligonucleotide-based therapeutics.

The partnership builds on GBI’s expertise in conjugation technologies and antibody manufacturing. Under the agreement, GBI will support miRecule in the development and clinical production of ARC products, which combine the precision of antibody targeting with the efficacy of RNA therapeutics. These therapies are positioned as a significant advancement in treating rare and challenging diseases with unmet medical needs.

“We are excited to work with GBI, whose expertise will propel our ARC technology into clinical development,” said Anthony Saleh, Ph.D., CEO of miRecule. He highlighted the potential for these therapies to offer meaningful benefits to patients, addressing the genetic causes of serious diseases.

Karl Pinto, Chairman and CEO of GBI Biomanufacturing, expressed the company’s commitment to advancing innovative therapeutics. “This partnership showcases our dedication to advancing ARC manufacturing and consolidating the development and production of both monoclonal antibodies and RNA bioconjugates,” he said. The collaboration is expected to streamline the path to clinical trials, benefiting from GBI’s extensive experience and investment in ARC technologies.